Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da Universidade Federal do Ceará (UFC) |
Texto Completo: | http://www.repositorio.ufc.br/handle/riufc/1899 |
Resumo: | Chronic hepatitis C has been associated with non-organ-specific autoantibodies (NOSA) production. Despite of increasing number of researches about this subject, there is no agreement among the authors of which autoantibodies are produced during combinated therapy of interferon and ribavirin or the clinical relevance of NOSA in patient’s organism. Our aim was to evaluate the profile of NOSA in patients with chronic hepatitis C who attended to Walter Cantídio Hospital (HUWC) and received combinated antiviral therapy (interferon-ribavirin). A total of 34 patients with hepatitis C were studied. Anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), anti-liver/kidney microsomal antibody type 1 (LKM-1) and anti-mitochondrial antibody (AMA) were detected by indirect immunofluorescence. The presence of NOSA was related to clinical and epidemiological variables and to the outcome of antiviral combination therapy with interferon-alfa and ribavirin. Patients were classified as nonresponders, relapsers or long-term responders depending on the outcome of treatment. In our study, before therapy, 23 patients were NOSA positive (SMA was detected in 6 patients, SMA and AMA in 10 and SMA, AMA and ANA in 7). On the 24th week of treatment, 24 patientes were NOSA positive (SMA was detected in 4 patients, SMA and AMA in 10, ANA and SMA in 1, ANA and AMA in 1 and SMA, AMA and ANA in 8). NOSA behavior did not show significant variation during treatment. The overall rate of long-term response was 26,5% (9/34). Long-term response occurred in 17,4% (4/23) of NOSA positive patients and 45,5% (5/11) of NOSA negative patients. Positivity of autoantibodies was not associated with gender, age, viral genotype or aminotransferase levels. In conclusion, ANA was the only NOSA associated with treatment outcome. The absence of NOSA might indicate a significantly higher chance for viral clearance in response to combination therapy for chronic hepatitis C infection. |
id |
UFC-7_e1c3dc47b404447bcdeba9160f14c707 |
---|---|
oai_identifier_str |
oai:repositorio.ufc.br:riufc/1899 |
network_acronym_str |
UFC-7 |
network_name_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository_id_str |
|
spelling |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirinaAutoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus RibavirinHepatite C crônicaAuto-ImunidadeInterferon alfaRibavirinaChronic hepatitis C has been associated with non-organ-specific autoantibodies (NOSA) production. Despite of increasing number of researches about this subject, there is no agreement among the authors of which autoantibodies are produced during combinated therapy of interferon and ribavirin or the clinical relevance of NOSA in patient’s organism. Our aim was to evaluate the profile of NOSA in patients with chronic hepatitis C who attended to Walter Cantídio Hospital (HUWC) and received combinated antiviral therapy (interferon-ribavirin). A total of 34 patients with hepatitis C were studied. Anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), anti-liver/kidney microsomal antibody type 1 (LKM-1) and anti-mitochondrial antibody (AMA) were detected by indirect immunofluorescence. The presence of NOSA was related to clinical and epidemiological variables and to the outcome of antiviral combination therapy with interferon-alfa and ribavirin. Patients were classified as nonresponders, relapsers or long-term responders depending on the outcome of treatment. In our study, before therapy, 23 patients were NOSA positive (SMA was detected in 6 patients, SMA and AMA in 10 and SMA, AMA and ANA in 7). On the 24th week of treatment, 24 patientes were NOSA positive (SMA was detected in 4 patients, SMA and AMA in 10, ANA and SMA in 1, ANA and AMA in 1 and SMA, AMA and ANA in 8). NOSA behavior did not show significant variation during treatment. The overall rate of long-term response was 26,5% (9/34). Long-term response occurred in 17,4% (4/23) of NOSA positive patients and 45,5% (5/11) of NOSA negative patients. Positivity of autoantibodies was not associated with gender, age, viral genotype or aminotransferase levels. In conclusion, ANA was the only NOSA associated with treatment outcome. The absence of NOSA might indicate a significantly higher chance for viral clearance in response to combination therapy for chronic hepatitis C infection.A hepatite crônica pelo vírus C tem sido associada à produção de autoanticorpos não-órgão específicos (NOSA). Apesar do aumento do número de pesquisas nessa área, ainda não existe um consenso entre quais autoanticorpos têm seus níveis elevados devido ao tratamento combinado de interferon e ribavirina, nem sua influência no desfecho do mesmo ou a relevância clínica da presença desses autoanticorpos no organismo do pacientes. O objetivo do presente estudo foi avaliar o perfil de NOSA em pacientes com hepatite C crônica atendidos no Hospital Universitário Walter Cantídio (HUWC) e submetidos à terapia combinada de interferon-alfa e ribavirina. Para isso, um total de 34 pacientes com hepatite C foram estudados. Os anticorpos anti-nuclear (FAN), anti-músculo liso (SMA), anti-microssomal de fígado e rim do tipo 1 (LKM-1) e anti-mitocôndria (AMA) foram detectados através de imunofluorescência indireta. A presença de NOSA foi relacionada a variáveis clínicas e epidemiológicas e à resposta ao tratamento. Os pacientes foram classificados, em relação à resposta ao tratamento, como não respondedores, recidivantes ou respondedores (resposta virológica sustentada). Em nosso estudo, 23 pacientes foram NOSA reagentes (SMA foi detectado em 6 pacientes, SMA e AMA em 10 e SMA, AMA e FAN em 7). Na 24ª semana de tratamento, 24 pacientes foram NOSA reagentes (SMA foi detectado em 4 pacientes, SMA e AMA em 10, FAN e SMA em 1, FAN e AMA em 1 e SMA, AMA e FAN em 8). A variação dos títulos dos autoanticorpos durante o tratamento não foi significativa. O percentual total de respondedores foi de 26,5% (9/34). A resposta virológica sustentada foi obtida por 17,4% (4/23) dos pacientes NOSA reagentes e 45,5% (5/11) dos pacientes não reagentes para NOSA. A presença de autoanticorpos não foi associada a gênero, idade, genótipo viral ou níveis de transaminases. Conclui-se que o FAN foi o único NOSA significativamente associado à resposta à terapia. A ausência de NOSA indica uma tendência à resposta virológica sustentada no tratamento da hepatite C crônica.Câmara , Lilia Maria CarneiroVilar, Janaina Leitão2012-02-02T16:24:57Z2012-02-02T16:24:57Z2006info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfVILAR, J. L. Perfil de autoanticorpos em pacientes com hepatite C e A influência do tratamento com interferon - alfa e ribavirina. 2006. 100 f. Dissertação (Mestrado em Microbiologia Médica) - Faculdade de Medicina. Universidade Federal do Ceará, Fortaleza, 2006.http://www.repositorio.ufc.br/handle/riufc/1899porreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccess2021-02-05T17:27:34Zoai:repositorio.ufc.br:riufc/1899Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-09-11T18:27:06.770844Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false |
dc.title.none.fl_str_mv |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina Autoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus Ribavirin |
title |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina |
spellingShingle |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina Vilar, Janaina Leitão Hepatite C crônica Auto-Imunidade Interferon alfa Ribavirina |
title_short |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina |
title_full |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina |
title_fullStr |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina |
title_full_unstemmed |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina |
title_sort |
Perfil de autoanticorpos em pacientes com hepatite c e a influência do tratamento com interferon-alfa e ribavirina |
author |
Vilar, Janaina Leitão |
author_facet |
Vilar, Janaina Leitão |
author_role |
author |
dc.contributor.none.fl_str_mv |
Câmara , Lilia Maria Carneiro |
dc.contributor.author.fl_str_mv |
Vilar, Janaina Leitão |
dc.subject.por.fl_str_mv |
Hepatite C crônica Auto-Imunidade Interferon alfa Ribavirina |
topic |
Hepatite C crônica Auto-Imunidade Interferon alfa Ribavirina |
description |
Chronic hepatitis C has been associated with non-organ-specific autoantibodies (NOSA) production. Despite of increasing number of researches about this subject, there is no agreement among the authors of which autoantibodies are produced during combinated therapy of interferon and ribavirin or the clinical relevance of NOSA in patient’s organism. Our aim was to evaluate the profile of NOSA in patients with chronic hepatitis C who attended to Walter Cantídio Hospital (HUWC) and received combinated antiviral therapy (interferon-ribavirin). A total of 34 patients with hepatitis C were studied. Anti-nuclear antibody (ANA), anti-smooth muscle antibody (SMA), anti-liver/kidney microsomal antibody type 1 (LKM-1) and anti-mitochondrial antibody (AMA) were detected by indirect immunofluorescence. The presence of NOSA was related to clinical and epidemiological variables and to the outcome of antiviral combination therapy with interferon-alfa and ribavirin. Patients were classified as nonresponders, relapsers or long-term responders depending on the outcome of treatment. In our study, before therapy, 23 patients were NOSA positive (SMA was detected in 6 patients, SMA and AMA in 10 and SMA, AMA and ANA in 7). On the 24th week of treatment, 24 patientes were NOSA positive (SMA was detected in 4 patients, SMA and AMA in 10, ANA and SMA in 1, ANA and AMA in 1 and SMA, AMA and ANA in 8). NOSA behavior did not show significant variation during treatment. The overall rate of long-term response was 26,5% (9/34). Long-term response occurred in 17,4% (4/23) of NOSA positive patients and 45,5% (5/11) of NOSA negative patients. Positivity of autoantibodies was not associated with gender, age, viral genotype or aminotransferase levels. In conclusion, ANA was the only NOSA associated with treatment outcome. The absence of NOSA might indicate a significantly higher chance for viral clearance in response to combination therapy for chronic hepatitis C infection. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006 2012-02-02T16:24:57Z 2012-02-02T16:24:57Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
VILAR, J. L. Perfil de autoanticorpos em pacientes com hepatite C e A influência do tratamento com interferon - alfa e ribavirina. 2006. 100 f. Dissertação (Mestrado em Microbiologia Médica) - Faculdade de Medicina. Universidade Federal do Ceará, Fortaleza, 2006. http://www.repositorio.ufc.br/handle/riufc/1899 |
identifier_str_mv |
VILAR, J. L. Perfil de autoanticorpos em pacientes com hepatite C e A influência do tratamento com interferon - alfa e ribavirina. 2006. 100 f. Dissertação (Mestrado em Microbiologia Médica) - Faculdade de Medicina. Universidade Federal do Ceará, Fortaleza, 2006. |
url |
http://www.repositorio.ufc.br/handle/riufc/1899 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Ceará (UFC) instname:Universidade Federal do Ceará (UFC) instacron:UFC |
instname_str |
Universidade Federal do Ceará (UFC) |
instacron_str |
UFC |
institution |
UFC |
reponame_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
collection |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC) |
repository.mail.fl_str_mv |
bu@ufc.br || repositorio@ufc.br |
_version_ |
1813028809242312704 |